» Articles » PMID: 24766775

Effects of Glucosamine and Risedronate Alone or in Combination in an Experimental Rabbit Model of Osteoarthritis

Overview
Journal BMC Vet Res
Publisher Biomed Central
Date 2014 Apr 29
PMID 24766775
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The osteoarthritis (OA) treatment in humans and in animals is a major orthopaedic challenge because there is not an ideal drug for preserving the joint structure and function. The aim of this study was to assess the effects of the treatment with oral glucosamine and risedronate alone or in combination on articular cartilage, synovial membrane and subchondral bone in an experimental rabbit model of OA. Osteoarthritis was surgically induced on one knee of 32 New Zealand White rabbits using the contralateral as healthy controls. Three weeks later treatments were started and lasted 8 weeks. Animal were divided in four groups of oral treatment: the first group received only saline, the second 21.5 mg/kg/day of glucosamine sulfate, the third 0.07 mg/kg/day of risedronate; and the fourth group both drugs simultaneously at the same dosages. Following sacrifice femurs were removed and osteochondral cylinders and synovial membrane were obtained for its histological and micro-CT evaluation.

Results: Sample analysis revealed that the model induced osteoarthritic changes in operated knees. OA placebo group showed a significant increase in cartilage thickness respect to the control and inflammatory changes in synovial membrane; whereas subchondral bone structure and volumetric bone mineral density remained unchanged. All the treated animals showed an improvement of the cartilage swelling independent of the drug used. Treatment with glucosamine alone seemed to have no effect in the progression of cartilage pathology while risedronate treatment had better results in superficial fibrillation and in resolving the inflammatory changes of the tissues, as well as modifying the orientation of trabecular lattice. The combination of both compounds seemed to have additive effects showing better results than those treated with only one drug.

Conclusions: The results of this animal study suggested that glucosamine sulfate and risedronate treatment alone or in combination may be able to stop cartilage swelling. The risedronate treatment could partially stop the fibrillation and the inflammation of synovial membrane as well as modify the orientation of trabeculae in healthy and in osteoarthritic knees.

Citing Articles

Effects of adenovirus-mediated knockdown of IRAK4 on synovitis in the osteoarthritis rabbit model.

Li M, Li H, Ran X, Yin H, Luo X, Chen Z Arthritis Res Ther. 2021; 23(1):294.

PMID: 34863246 PMC: 8643028. DOI: 10.1186/s13075-021-02684-8.


Histomorphometric Quantitative Evaluation of Long-Term Risedronate Use in a Knee Osteoarthritis Rabbit Model.

Fernandez-Martin S, Gonzalez-Cantalapiedra A, Permuy M, Garcia-Gonzalez M, Lopez-Pena M, Munoz F Front Vet Sci. 2021; 8:669815.

PMID: 33969044 PMC: 8100024. DOI: 10.3389/fvets.2021.669815.


Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020.

Fernandez-Martin S, Lopez-Pena M, Munoz F, Permuy M, Gonzalez-Cantalapiedra A Arthritis Res Ther. 2021; 23(1):60.

PMID: 33618776 PMC: 7898436. DOI: 10.1186/s13075-021-02446-6.


No Effect of Long-Term Risedronate Use on Cartilage and Subchondral Bone in an Experimental Rabbit Model of Osteoarthritis.

Fernandez-Martin S, Permuy M, Lopez-Pena M, Munoz F, Gonzalez-Cantalapiedra A Front Vet Sci. 2020; 7:576212.

PMID: 33240955 PMC: 7667022. DOI: 10.3389/fvets.2020.576212.


Protective effect of glucosamine and risedronate (alone or in combination) against osteoarthritic changes in rat experimental model of immobilized knee.

Salman A, Shabana A, El-Ghazouly D, Maha E Anat Cell Biol. 2020; 52(4):498-510.

PMID: 31949990 PMC: 6952695. DOI: 10.5115/acb.19.050.


References
1.
Xie L, Lin A, Levenston M, Guldberg R . Quantitative assessment of articular cartilage morphology via EPIC-microCT. Osteoarthritis Cartilage. 2008; 17(3):313-20. PMC: 2683349. DOI: 10.1016/j.joca.2008.07.015. View

2.
Garnero P, Christgau S, Delmas P . The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone. 2001; 28(5):461-4. DOI: 10.1016/s8756-3282(01)00431-8. View

3.
Da Camara C, Dowless G . Glucosamine sulfate for osteoarthritis. Ann Pharmacother. 1998; 32(5):580-7. DOI: 10.1345/aph.17214. View

4.
Myers S, Brandt K, Burr D, OConnor B, Albrecht M . Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol. 1999; 26(12):2645-53. View

5.
Spector T . Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res. 2004; 15(5):413-8. DOI: 10.1007/BF03327362. View